Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera seeks to raise up to $292.2 million in US IPO Venture capital firm ARCH Ventures founded Metsera in 2022 Jan 27 (Reuters) - Metsera, which is developing weight-loss drugs, said on Monday ...

US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is ...

(Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable ...